Click to cancel search
Login
Sign Up
Home Page
How It Works
Our Story
Symptom Checker
Second Opinion Finder
Newsroom
Partner With Us
MediFind Pro
FAQ
Are we missing a condition or feature you’d like to see? MediFind is always evolving and we’d love your feedback.
Submit Feedback
Advertising Policy
Privacy Policy
Terms & Conditions
Condition
Condition
Doctor
Symptom
Condition
Click to search for condition or expert
Login
Sign Up
Click to open main menu
Share
Share
Share
Click
Share
Share
Condition
Acrospiroma
Symptoms, Doctors, Treatments, Research & More
Overview
Find a Doctor
Latest Research
Clinical Trials
Condition 101
What are the alternative names for Acrospiroma?
Hidradenoma
Eccrine Acrospiroma
Top Global Doctors
Click to see doctor options
EC
Elite
Eduardo J. Calonje
London, ENG, GB
Click to see doctor options
DK
Elite
Dmitry V. Kazakov
Pilsen, PL, CZ
Click to see doctor options
AK
Elite
Anastasia M. Konstantinova
Saint Petersburg, SPE, RU
Click to see doctor options
DK
Elite
Denisa Kacerovska
Pilsen, PL, CZ
Click to see doctor options
LR
Elite
Luis Requena
Madrid, MD, ES
Click to see doctor options
HK
Elite
Heinz Kutzner
Friedrichshafen, BW, DE
Latest Research
Latest Advance
Study
Condition:
Eccrine Porocarcinoma of the Head and Neck
Journal:
Head & neck
Treatment Used:
Surgical Removal
Number of Patients:
116
Published —
April 22, 2020
The study researched the outcomes of surgical resection of eccrine porocarcinoma of the head and neck.
Latest Advance
Study
Condition:
Multiple eccrine hidrocystomas
Journal:
Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology
Treatment Used:
Intralesional botulinum toxin-A injection
Number of Patients:
20
Published —
February 01, 2018
The study researched the effects of intralesional botulinum toxin-A injection for patients with multiple eccrine hidrocystomas.
Clinical Trials
Clinical Trial
Biological
Status:
Recruiting
Study Type:
Biological
Participants:
68
Start Date:
September 18, 2017
A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors
